Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study to Evaluate the Feasibility and Tolerability of Treatment of Previously Untreated B-CLL Chronic Lymphocytic Leukemia (B-CLL) Patients With Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF

NCT00302861 is registered in ClinicalTrials.gov with Genitope Corporation as lead sponsor.

NCT NCT00302861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00302861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study to Evaluate the Feasibility and Tolerability of Treatment of Previously Untreated B-CLL Chronic Lymphocytic Leukemia (B-CLL) Patients With Recombinant Idiotype Conjugated to KLH (Id-KLH) Administered With GM-CSF
Lead sponsor
Genitope Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2006
Completion date
Not reported
Enrollment
86
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia